The SGLT2 inhibitor, already approved for some high-risk heart failure patients, has now received a much wider approval. 

Waiting a few additional weeks, the agency wrote, could help limit myocarditis or pericarditis among young adults.

The new analysis focused on both primary and secondary MR 12 months after TEER. 

Researchers at Gladstone Institutes developed a new algorithm method for identifying genetic variant combinations that are likely to play important roles in congenital heart disease.

The medication, originally developed to treat celiac disease, could provide significant relief for young MIS-C patients. 

The team's findings, one researcher said, "could eventually make a huge impact on many patients lives."

Researchers focused on 30-day outcomes, sharing their findings in the American Journal of Cardiology.

Don't give up on eating vegetables quite yet—but a new analysis in Frontiers in Nutrition does suggest they can't protect you from CVD all on their own. 

UHG called the federal government's position "deeply flawed" and said it plans to "defend our case vigorously" in court.